Please upgrade your browser.
Approval was based on data from the Phase III CheckMate -214 clinical trial, in which the Opdivo (nivolumab) + Yervoy (ipilimumab) combination showed “a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib,” according to BMS.
It may be time to adopt a broader approach to tumor and matched normal sequencing in patients with advanced renal cell carcinoma (RCC), according to a large new study.
Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic
Anastomosing hemangioma (ah) is a rare subtype of primary vascular tumour that can, clinically and radiologically, present similarly to malignant renal tumours such as renal cell carcinoma (rcc) and angiosarcoma.
Checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) monoclonal antibodies have changed profoundly the treatment of melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and bladder cancer. Currently, they are tested in various tumor entities as monotherapy or in combination with chemotherapies or targeted therapies. However, only a subgroup of patients benefit from checkpoint blockade (combinations).
A comprehensive study by the Keck School of Medicine of USC has found that robotic partial nephrectomy offers significantly better patient outcomes.
Nine-year-old JaKiah Collins had a big doctor's appointment ahead of her. She was used to coming to the hospital; she'd been in and out of hospitals for years. But this appointment was a big milestone.
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib
A world-first discovery by University of Otago scientists may change the way children suffering from a rare form of kidney cancer are treated.
Once in a rare while, we hear a story of someone given months or weeks to live who ends up surviving and defiantly thriving. Like the first person to run a four-minute mile, climb Mt. Everest, or walk on the moon, such individuals are living proof that the impossible is possible. Yet because their experience is so far outside the norm, these survivors have been labeled medical anomalies and set aside from the lens of research. That is, until Kelly Turner, PhD, came along. The author of Radical Remission: Surviving Cancer Against All Odds (HarperCollins, 2014), Turner has studied hundreds of spontaneous-remission cases to see what can be learned from them.
Many cases of early-stage kidney cancer can be treated with a relatively new, nonsurgical procedure used to destroy tumors, a new study by a team led by Weill Cornell Medicine and NewYork-Presbyterian suggests. The procedure, called percutaneous ablation, involves the insertion of a needle.
|Powered by NeonCRM|